Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048809391> ?p ?o ?g. }
- W3048809391 endingPage "B051" @default.
- W3048809391 startingPage "B051" @default.
- W3048809391 abstract "Abstract Purpose: Men of African ancestry experience an excessive prostate cancer mortality that could be related to an aggressive tumor biology. We previously described an immune-inflammation signature in prostate tumors of African-American patients. Here, we further deconstructed this signature and investigated its relationships with tumor biology, survival, and a common germline variant in the interferon λ4 (IFNL4) gene. Experimental Design: We analyzed gene expression in prostate tissue datasets and performed IFNL4 genotype and survival analyses. We also overexpressed IFNL4 in human prostate cancer cells. Results: We found that a distinct interferon signature that is analogous to the previously described “Interferon-related DNA Damage Resistance Signature” (IRDS) occurs in prostate tumors. Evaluation of two independent patient cohorts revealed that IRDS is detected about twice as often in prostate tumors of African-American than European-American men. Furthermore, analysis in The Cancer Genome Atlas (TCGA) showed an association of increased IRDS in prostate tumors with decreased disease-free survival. To explain these observations, we assessed whether IRDS is associated with an IFNL4 germline variant (rs368234815-ΔG) that controls production of IFN-λ4 protein, a type-III interferon, and is most common in individuals of African ancestry. We show that the IFNL4 rs368234815-ΔG allele was significantly associated with IRDS in prostate tumors and overall survival of African-American patients. Moreover, IFNL4 overexpression induced IRDS-like signatures in three human prostate cancer cell lines. Conclusions: Tumor interferon signaling has recently been shown to modulate response and resistance to immune checkpoint blockade. Here, we describe a distinct and biologically relevant interferon signature, IRDS, in prostate tumors that has a high prevalence in African-American patients. Our observations indicate that IRDS and IFNL4 rs368234815-ΔG may have a function in the tumor biology and survival of African-American patients, and influence immune therapy outcomes, which should be examined in future studies. Citation Format: Wei Tang, Tiffany Wallace, Ming Yi, Cristina Magi-Galluzzi, Tiffany Dorsey, Olusegun Onabajo, Adeola Obajemu, Symone Jordan, Christopher Loffredo, Robert Stephens, Robert Silverman, George Stark, Eric Klein, Ludmila Prokunina-Olsson, Stefan Ambs. IFNL4-deltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer [abstract]. In: Proceedings of the Eleventh AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2018 Nov 2-5; New Orleans, LA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl):Abstract nr B051." @default.
- W3048809391 created "2020-08-18" @default.
- W3048809391 creator A5001220023 @default.
- W3048809391 creator A5009225928 @default.
- W3048809391 creator A5009724115 @default.
- W3048809391 creator A5024110359 @default.
- W3048809391 creator A5027170042 @default.
- W3048809391 creator A5034716746 @default.
- W3048809391 creator A5047942023 @default.
- W3048809391 creator A5048657439 @default.
- W3048809391 creator A5063851986 @default.
- W3048809391 creator A5066025552 @default.
- W3048809391 creator A5067358586 @default.
- W3048809391 creator A5085143863 @default.
- W3048809391 creator A5090265942 @default.
- W3048809391 creator A5090427988 @default.
- W3048809391 creator A5091893726 @default.
- W3048809391 date "2020-06-01" @default.
- W3048809391 modified "2023-10-18" @default.
- W3048809391 title "Abstract B051: IFNL4-deltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer" @default.
- W3048809391 doi "https://doi.org/10.1158/1538-7755.disp18-b051" @default.
- W3048809391 hasPublicationYear "2020" @default.
- W3048809391 type Work @default.
- W3048809391 sameAs 3048809391 @default.
- W3048809391 citedByCount "1" @default.
- W3048809391 countsByYear W30488093912021 @default.
- W3048809391 crossrefType "journal-article" @default.
- W3048809391 hasAuthorship W3048809391A5001220023 @default.
- W3048809391 hasAuthorship W3048809391A5009225928 @default.
- W3048809391 hasAuthorship W3048809391A5009724115 @default.
- W3048809391 hasAuthorship W3048809391A5024110359 @default.
- W3048809391 hasAuthorship W3048809391A5027170042 @default.
- W3048809391 hasAuthorship W3048809391A5034716746 @default.
- W3048809391 hasAuthorship W3048809391A5047942023 @default.
- W3048809391 hasAuthorship W3048809391A5048657439 @default.
- W3048809391 hasAuthorship W3048809391A5063851986 @default.
- W3048809391 hasAuthorship W3048809391A5066025552 @default.
- W3048809391 hasAuthorship W3048809391A5067358586 @default.
- W3048809391 hasAuthorship W3048809391A5085143863 @default.
- W3048809391 hasAuthorship W3048809391A5090265942 @default.
- W3048809391 hasAuthorship W3048809391A5090427988 @default.
- W3048809391 hasAuthorship W3048809391A5091893726 @default.
- W3048809391 hasConcept C104317684 @default.
- W3048809391 hasConcept C109825262 @default.
- W3048809391 hasConcept C121608353 @default.
- W3048809391 hasConcept C126322002 @default.
- W3048809391 hasConcept C135763542 @default.
- W3048809391 hasConcept C143998085 @default.
- W3048809391 hasConcept C150194340 @default.
- W3048809391 hasConcept C180754005 @default.
- W3048809391 hasConcept C203014093 @default.
- W3048809391 hasConcept C2776178377 @default.
- W3048809391 hasConcept C2776235491 @default.
- W3048809391 hasConcept C2777701055 @default.
- W3048809391 hasConcept C2779733811 @default.
- W3048809391 hasConcept C2780192828 @default.
- W3048809391 hasConcept C502942594 @default.
- W3048809391 hasConcept C54355233 @default.
- W3048809391 hasConcept C71924100 @default.
- W3048809391 hasConcept C86803240 @default.
- W3048809391 hasConcept C8891405 @default.
- W3048809391 hasConceptScore W3048809391C104317684 @default.
- W3048809391 hasConceptScore W3048809391C109825262 @default.
- W3048809391 hasConceptScore W3048809391C121608353 @default.
- W3048809391 hasConceptScore W3048809391C126322002 @default.
- W3048809391 hasConceptScore W3048809391C135763542 @default.
- W3048809391 hasConceptScore W3048809391C143998085 @default.
- W3048809391 hasConceptScore W3048809391C150194340 @default.
- W3048809391 hasConceptScore W3048809391C180754005 @default.
- W3048809391 hasConceptScore W3048809391C203014093 @default.
- W3048809391 hasConceptScore W3048809391C2776178377 @default.
- W3048809391 hasConceptScore W3048809391C2776235491 @default.
- W3048809391 hasConceptScore W3048809391C2777701055 @default.
- W3048809391 hasConceptScore W3048809391C2779733811 @default.
- W3048809391 hasConceptScore W3048809391C2780192828 @default.
- W3048809391 hasConceptScore W3048809391C502942594 @default.
- W3048809391 hasConceptScore W3048809391C54355233 @default.
- W3048809391 hasConceptScore W3048809391C71924100 @default.
- W3048809391 hasConceptScore W3048809391C86803240 @default.
- W3048809391 hasConceptScore W3048809391C8891405 @default.
- W3048809391 hasIssue "6_Supplement_1" @default.
- W3048809391 hasLocation W30488093911 @default.
- W3048809391 hasOpenAccess W3048809391 @default.
- W3048809391 hasPrimaryLocation W30488093911 @default.
- W3048809391 hasRelatedWork W1980245127 @default.
- W3048809391 hasRelatedWork W2117622607 @default.
- W3048809391 hasRelatedWork W2188535921 @default.
- W3048809391 hasRelatedWork W2547794367 @default.
- W3048809391 hasRelatedWork W3154617653 @default.
- W3048809391 hasRelatedWork W3203489722 @default.
- W3048809391 hasRelatedWork W4234606113 @default.
- W3048809391 hasRelatedWork W4360983034 @default.
- W3048809391 hasRelatedWork W4386958104 @default.
- W3048809391 hasRelatedWork W1896726944 @default.
- W3048809391 hasVolume "29" @default.
- W3048809391 isParatext "false" @default.
- W3048809391 isRetracted "false" @default.
- W3048809391 magId "3048809391" @default.